The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
Lenalidomide (Revlimid®) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, and in combination with dexam...
Gespeichert in:
| Veröffentlicht in: | Microvascular research 2009-03, Vol.77 (2), p.78-86 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 86 |
|---|---|
| container_issue | 2 |
| container_start_page | 78 |
| container_title | Microvascular research |
| container_volume | 77 |
| creator | Lu, Ling Payvandi, Faribourz Wu, Lei Zhang, Ling-Hua Hariri, Robert J Man, Hon-Wah Chen, Roger S. Muller, George W. Hughes, Christopher C.W. Stirling, David I. Schafer, Peter H. Bartlett, J. Blake |
| description | Lenalidomide (Revlimid®) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, and in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Previous reports suggest that lenalidomide is anti-angiogenic and this property appears to be related to efficacy in patients with MDS. We have investigated the effect of lenalidomide on the formation of microvessels in a novel
in vitro angiogenesis assay utilizing human umbilical arterial rings and in a capillary-like cord formation assay using cultured primary endothelial cells. We found that lenalidomide consistently inhibits both sprout formation by arterial rings and cord formation by endothelial cells in a dose-dependent manner. We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, β-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Furthermore, lenalidomide inhibited VEGF-induced PI3K–Akt pathway signaling, which is known to regulate adherens junction formation. We also found a strong inhibitory effect of lenalidomide on hypoxia-induced endothelial cell formation of cords and HIF-1α expression, the main mediator of hypoxia-mediated effects and a key driver of angiogenesis and metastasis. Anti-metastatic activity of lenalidomide
in vivo was confirmed in the B16-F10 mouse melanoma model by a >
40% reduction in melanoma lung colony counts versus untreated mice. Our results suggest that inhibitory effects on microvessel formation, in particular adherens junction formation and inhibition of hypoxia-induced processes support a potential anti-angiogenic and anti-metastatic mechanism for this clinically active drug. |
| doi_str_mv | 10.1016/j.mvr.2008.08.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66972703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0026286208001301</els_id><sourcerecordid>66972703</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-50f155c0c64e1847c4c4d87954e9f0d2e14dfad4204285ebc533a10fe59359493</originalsourceid><addsrcrecordid>eNp9kVGPEyEUhYnRuN3VH-CL4cm3qTADM0N8MptVN9nEl_WZULjT3oaBCjON_UP-Tpm20TeTk8AN3zkBDiHvOFtzxtuP-_V4TOuasX69iDUvyIozJSvVcPWSrBir26ru2_qG3Oa8Z4xzqerX5Ib3PZOiaVbk9_MOqAkTVtYEC4m6NG-ph2A8ujiiA4phhxuccsG2GLcQIOMyODrCZHJRGY9o6Dj7CQ_-ryOmE4VhAFu8MVAILk478Gg8teA9HeZgJywnGGiIaYy_0J5zd6fDeW9jcLgQ-Q15NRif4e11vSM_vjw833-rnr5_fbz__FRZwbupkmzgUlpmWwG8F50VVri-U1KAGpirgQs3GCdqJupewsbKpjGcDSBVI5VQzR35cMk9pPhzhjzpEfNyWRMgzlm3rerqjjUF5BfQpphzgkEfEo4mnTRneilH73UpRy_l6EVnz_tr-LwZwf1zXNsowKcLAOWJR4Sks0UotThM5Re1i_if-D-cyaRQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66972703</pqid></control><display><type>article</type><title>The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Collection</source><creator>Lu, Ling ; Payvandi, Faribourz ; Wu, Lei ; Zhang, Ling-Hua ; Hariri, Robert J ; Man, Hon-Wah ; Chen, Roger S. ; Muller, George W. ; Hughes, Christopher C.W. ; Stirling, David I. ; Schafer, Peter H. ; Bartlett, J. Blake</creator><creatorcontrib>Lu, Ling ; Payvandi, Faribourz ; Wu, Lei ; Zhang, Ling-Hua ; Hariri, Robert J ; Man, Hon-Wah ; Chen, Roger S. ; Muller, George W. ; Hughes, Christopher C.W. ; Stirling, David I. ; Schafer, Peter H. ; Bartlett, J. Blake</creatorcontrib><description>Lenalidomide (Revlimid®) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, and in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Previous reports suggest that lenalidomide is anti-angiogenic and this property appears to be related to efficacy in patients with MDS. We have investigated the effect of lenalidomide on the formation of microvessels in a novel
in vitro angiogenesis assay utilizing human umbilical arterial rings and in a capillary-like cord formation assay using cultured primary endothelial cells. We found that lenalidomide consistently inhibits both sprout formation by arterial rings and cord formation by endothelial cells in a dose-dependent manner. We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, β-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Furthermore, lenalidomide inhibited VEGF-induced PI3K–Akt pathway signaling, which is known to regulate adherens junction formation. We also found a strong inhibitory effect of lenalidomide on hypoxia-induced endothelial cell formation of cords and HIF-1α expression, the main mediator of hypoxia-mediated effects and a key driver of angiogenesis and metastasis. Anti-metastatic activity of lenalidomide
in vivo was confirmed in the B16-F10 mouse melanoma model by a >
40% reduction in melanoma lung colony counts versus untreated mice. Our results suggest that inhibitory effects on microvessel formation, in particular adherens junction formation and inhibition of hypoxia-induced processes support a potential anti-angiogenic and anti-metastatic mechanism for this clinically active drug.</description><identifier>ISSN: 0026-2862</identifier><identifier>EISSN: 1095-9319</identifier><identifier>DOI: 10.1016/j.mvr.2008.08.003</identifier><identifier>PMID: 18805433</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adherens Junctions - drug effects ; Akt ; Angiogenesis ; Angiogenesis Inhibitors - pharmacology ; Animals ; Antigens, CD - metabolism ; Antineoplastic Agents - pharmacology ; Basic Helix-Loop-Helix Transcription Factors - metabolism ; beta Catenin - metabolism ; Cadherin ; Cadherins - metabolism ; Cell Differentiation - drug effects ; Cell Hypoxia ; Cell Line, Tumor ; Cells, Cultured ; Endothelial Cells - drug effects ; Endothelial Cells - pathology ; Female ; HIF-1α ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism ; IMiDs ; In Vitro Techniques ; Lenalidomide ; Lung Neoplasms - prevention & control ; Lung Neoplasms - secondary ; Melanoma, Experimental - drug therapy ; Metastasis ; Mice ; Microcirculation - drug effects ; Neoplasm Metastasis - prevention & control ; Neovascularization, Pathologic - prevention & control ; Platelet Endothelial Cell Adhesion Molecule-1 - metabolism ; Pregnancy ; Proto-Oncogene Proteins c-akt - metabolism ; Thalidomide - analogs & derivatives ; Thalidomide - pharmacology ; Umbilical Arteries - drug effects ; Umbilical Arteries - growth & development</subject><ispartof>Microvascular research, 2009-03, Vol.77 (2), p.78-86</ispartof><rights>2008 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-50f155c0c64e1847c4c4d87954e9f0d2e14dfad4204285ebc533a10fe59359493</citedby><cites>FETCH-LOGICAL-c417t-50f155c0c64e1847c4c4d87954e9f0d2e14dfad4204285ebc533a10fe59359493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0026286208001301$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18805433$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Ling</creatorcontrib><creatorcontrib>Payvandi, Faribourz</creatorcontrib><creatorcontrib>Wu, Lei</creatorcontrib><creatorcontrib>Zhang, Ling-Hua</creatorcontrib><creatorcontrib>Hariri, Robert J</creatorcontrib><creatorcontrib>Man, Hon-Wah</creatorcontrib><creatorcontrib>Chen, Roger S.</creatorcontrib><creatorcontrib>Muller, George W.</creatorcontrib><creatorcontrib>Hughes, Christopher C.W.</creatorcontrib><creatorcontrib>Stirling, David I.</creatorcontrib><creatorcontrib>Schafer, Peter H.</creatorcontrib><creatorcontrib>Bartlett, J. Blake</creatorcontrib><title>The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions</title><title>Microvascular research</title><addtitle>Microvasc Res</addtitle><description>Lenalidomide (Revlimid®) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, and in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Previous reports suggest that lenalidomide is anti-angiogenic and this property appears to be related to efficacy in patients with MDS. We have investigated the effect of lenalidomide on the formation of microvessels in a novel
in vitro angiogenesis assay utilizing human umbilical arterial rings and in a capillary-like cord formation assay using cultured primary endothelial cells. We found that lenalidomide consistently inhibits both sprout formation by arterial rings and cord formation by endothelial cells in a dose-dependent manner. We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, β-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Furthermore, lenalidomide inhibited VEGF-induced PI3K–Akt pathway signaling, which is known to regulate adherens junction formation. We also found a strong inhibitory effect of lenalidomide on hypoxia-induced endothelial cell formation of cords and HIF-1α expression, the main mediator of hypoxia-mediated effects and a key driver of angiogenesis and metastasis. Anti-metastatic activity of lenalidomide
in vivo was confirmed in the B16-F10 mouse melanoma model by a >
40% reduction in melanoma lung colony counts versus untreated mice. Our results suggest that inhibitory effects on microvessel formation, in particular adherens junction formation and inhibition of hypoxia-induced processes support a potential anti-angiogenic and anti-metastatic mechanism for this clinically active drug.</description><subject>Adherens Junctions - drug effects</subject><subject>Akt</subject><subject>Angiogenesis</subject><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Animals</subject><subject>Antigens, CD - metabolism</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Basic Helix-Loop-Helix Transcription Factors - metabolism</subject><subject>beta Catenin - metabolism</subject><subject>Cadherin</subject><subject>Cadherins - metabolism</subject><subject>Cell Differentiation - drug effects</subject><subject>Cell Hypoxia</subject><subject>Cell Line, Tumor</subject><subject>Cells, Cultured</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - pathology</subject><subject>Female</subject><subject>HIF-1α</subject><subject>Humans</subject><subject>Hypoxia-Inducible Factor 1, alpha Subunit - metabolism</subject><subject>IMiDs</subject><subject>In Vitro Techniques</subject><subject>Lenalidomide</subject><subject>Lung Neoplasms - prevention & control</subject><subject>Lung Neoplasms - secondary</subject><subject>Melanoma, Experimental - drug therapy</subject><subject>Metastasis</subject><subject>Mice</subject><subject>Microcirculation - drug effects</subject><subject>Neoplasm Metastasis - prevention & control</subject><subject>Neovascularization, Pathologic - prevention & control</subject><subject>Platelet Endothelial Cell Adhesion Molecule-1 - metabolism</subject><subject>Pregnancy</subject><subject>Proto-Oncogene Proteins c-akt - metabolism</subject><subject>Thalidomide - analogs & derivatives</subject><subject>Thalidomide - pharmacology</subject><subject>Umbilical Arteries - drug effects</subject><subject>Umbilical Arteries - growth & development</subject><issn>0026-2862</issn><issn>1095-9319</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kVGPEyEUhYnRuN3VH-CL4cm3qTADM0N8MptVN9nEl_WZULjT3oaBCjON_UP-Tpm20TeTk8AN3zkBDiHvOFtzxtuP-_V4TOuasX69iDUvyIozJSvVcPWSrBir26ru2_qG3Oa8Z4xzqerX5Ib3PZOiaVbk9_MOqAkTVtYEC4m6NG-ph2A8ujiiA4phhxuccsG2GLcQIOMyODrCZHJRGY9o6Dj7CQ_-ryOmE4VhAFu8MVAILk478Gg8teA9HeZgJywnGGiIaYy_0J5zd6fDeW9jcLgQ-Q15NRif4e11vSM_vjw833-rnr5_fbz__FRZwbupkmzgUlpmWwG8F50VVri-U1KAGpirgQs3GCdqJupewsbKpjGcDSBVI5VQzR35cMk9pPhzhjzpEfNyWRMgzlm3rerqjjUF5BfQpphzgkEfEo4mnTRneilH73UpRy_l6EVnz_tr-LwZwf1zXNsowKcLAOWJR4Sks0UotThM5Re1i_if-D-cyaRQ</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Lu, Ling</creator><creator>Payvandi, Faribourz</creator><creator>Wu, Lei</creator><creator>Zhang, Ling-Hua</creator><creator>Hariri, Robert J</creator><creator>Man, Hon-Wah</creator><creator>Chen, Roger S.</creator><creator>Muller, George W.</creator><creator>Hughes, Christopher C.W.</creator><creator>Stirling, David I.</creator><creator>Schafer, Peter H.</creator><creator>Bartlett, J. Blake</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090301</creationdate><title>The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions</title><author>Lu, Ling ; Payvandi, Faribourz ; Wu, Lei ; Zhang, Ling-Hua ; Hariri, Robert J ; Man, Hon-Wah ; Chen, Roger S. ; Muller, George W. ; Hughes, Christopher C.W. ; Stirling, David I. ; Schafer, Peter H. ; Bartlett, J. Blake</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-50f155c0c64e1847c4c4d87954e9f0d2e14dfad4204285ebc533a10fe59359493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adherens Junctions - drug effects</topic><topic>Akt</topic><topic>Angiogenesis</topic><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Animals</topic><topic>Antigens, CD - metabolism</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Basic Helix-Loop-Helix Transcription Factors - metabolism</topic><topic>beta Catenin - metabolism</topic><topic>Cadherin</topic><topic>Cadherins - metabolism</topic><topic>Cell Differentiation - drug effects</topic><topic>Cell Hypoxia</topic><topic>Cell Line, Tumor</topic><topic>Cells, Cultured</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - pathology</topic><topic>Female</topic><topic>HIF-1α</topic><topic>Humans</topic><topic>Hypoxia-Inducible Factor 1, alpha Subunit - metabolism</topic><topic>IMiDs</topic><topic>In Vitro Techniques</topic><topic>Lenalidomide</topic><topic>Lung Neoplasms - prevention & control</topic><topic>Lung Neoplasms - secondary</topic><topic>Melanoma, Experimental - drug therapy</topic><topic>Metastasis</topic><topic>Mice</topic><topic>Microcirculation - drug effects</topic><topic>Neoplasm Metastasis - prevention & control</topic><topic>Neovascularization, Pathologic - prevention & control</topic><topic>Platelet Endothelial Cell Adhesion Molecule-1 - metabolism</topic><topic>Pregnancy</topic><topic>Proto-Oncogene Proteins c-akt - metabolism</topic><topic>Thalidomide - analogs & derivatives</topic><topic>Thalidomide - pharmacology</topic><topic>Umbilical Arteries - drug effects</topic><topic>Umbilical Arteries - growth & development</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Ling</creatorcontrib><creatorcontrib>Payvandi, Faribourz</creatorcontrib><creatorcontrib>Wu, Lei</creatorcontrib><creatorcontrib>Zhang, Ling-Hua</creatorcontrib><creatorcontrib>Hariri, Robert J</creatorcontrib><creatorcontrib>Man, Hon-Wah</creatorcontrib><creatorcontrib>Chen, Roger S.</creatorcontrib><creatorcontrib>Muller, George W.</creatorcontrib><creatorcontrib>Hughes, Christopher C.W.</creatorcontrib><creatorcontrib>Stirling, David I.</creatorcontrib><creatorcontrib>Schafer, Peter H.</creatorcontrib><creatorcontrib>Bartlett, J. Blake</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Microvascular research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Ling</au><au>Payvandi, Faribourz</au><au>Wu, Lei</au><au>Zhang, Ling-Hua</au><au>Hariri, Robert J</au><au>Man, Hon-Wah</au><au>Chen, Roger S.</au><au>Muller, George W.</au><au>Hughes, Christopher C.W.</au><au>Stirling, David I.</au><au>Schafer, Peter H.</au><au>Bartlett, J. Blake</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions</atitle><jtitle>Microvascular research</jtitle><addtitle>Microvasc Res</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>77</volume><issue>2</issue><spage>78</spage><epage>86</epage><pages>78-86</pages><issn>0026-2862</issn><eissn>1095-9319</eissn><abstract>Lenalidomide (Revlimid®) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, and in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Previous reports suggest that lenalidomide is anti-angiogenic and this property appears to be related to efficacy in patients with MDS. We have investigated the effect of lenalidomide on the formation of microvessels in a novel
in vitro angiogenesis assay utilizing human umbilical arterial rings and in a capillary-like cord formation assay using cultured primary endothelial cells. We found that lenalidomide consistently inhibits both sprout formation by arterial rings and cord formation by endothelial cells in a dose-dependent manner. We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, β-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Furthermore, lenalidomide inhibited VEGF-induced PI3K–Akt pathway signaling, which is known to regulate adherens junction formation. We also found a strong inhibitory effect of lenalidomide on hypoxia-induced endothelial cell formation of cords and HIF-1α expression, the main mediator of hypoxia-mediated effects and a key driver of angiogenesis and metastasis. Anti-metastatic activity of lenalidomide
in vivo was confirmed in the B16-F10 mouse melanoma model by a >
40% reduction in melanoma lung colony counts versus untreated mice. Our results suggest that inhibitory effects on microvessel formation, in particular adherens junction formation and inhibition of hypoxia-induced processes support a potential anti-angiogenic and anti-metastatic mechanism for this clinically active drug.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18805433</pmid><doi>10.1016/j.mvr.2008.08.003</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0026-2862 |
| ispartof | Microvascular research, 2009-03, Vol.77 (2), p.78-86 |
| issn | 0026-2862 1095-9319 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66972703 |
| source | MEDLINE; Elsevier ScienceDirect Journals Collection |
| subjects | Adherens Junctions - drug effects Akt Angiogenesis Angiogenesis Inhibitors - pharmacology Animals Antigens, CD - metabolism Antineoplastic Agents - pharmacology Basic Helix-Loop-Helix Transcription Factors - metabolism beta Catenin - metabolism Cadherin Cadherins - metabolism Cell Differentiation - drug effects Cell Hypoxia Cell Line, Tumor Cells, Cultured Endothelial Cells - drug effects Endothelial Cells - pathology Female HIF-1α Humans Hypoxia-Inducible Factor 1, alpha Subunit - metabolism IMiDs In Vitro Techniques Lenalidomide Lung Neoplasms - prevention & control Lung Neoplasms - secondary Melanoma, Experimental - drug therapy Metastasis Mice Microcirculation - drug effects Neoplasm Metastasis - prevention & control Neovascularization, Pathologic - prevention & control Platelet Endothelial Cell Adhesion Molecule-1 - metabolism Pregnancy Proto-Oncogene Proteins c-akt - metabolism Thalidomide - analogs & derivatives Thalidomide - pharmacology Umbilical Arteries - drug effects Umbilical Arteries - growth & development |
| title | The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A46%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20anti-cancer%20drug%20lenalidomide%20inhibits%20angiogenesis%20and%20metastasis%20via%20multiple%20inhibitory%20effects%20on%20endothelial%20cell%20function%20in%20normoxic%20and%20hypoxic%20conditions&rft.jtitle=Microvascular%20research&rft.au=Lu,%20Ling&rft.date=2009-03-01&rft.volume=77&rft.issue=2&rft.spage=78&rft.epage=86&rft.pages=78-86&rft.issn=0026-2862&rft.eissn=1095-9319&rft_id=info:doi/10.1016/j.mvr.2008.08.003&rft_dat=%3Cproquest_cross%3E66972703%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66972703&rft_id=info:pmid/18805433&rft_els_id=S0026286208001301&rfr_iscdi=true |